Stereotactic body radiation therapy for melanoma and renal cell carcinoma: Impact of single fraction equivalent dose on local control

Radiation Oncology

Volumn 6, Issue 1, 2011, Pages

  Stinauer, Michelle A ^a   Kavanagh, Brian D ^a   Schefter, Tracey E ^a   Gonzalez, Rene ^a   Flaig, Thomas ^a   Lewis, Karl ^a   Robinson, William ^a   Chidel, Mark ^b   Glode, Michael ^a   Raben, David ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b Exempla Saint Joseph Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BONE; CANCER PATIENT; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HALF LIFE TIME; HISTOLOGY; HUMAN; KIDNEY CARCINOMA; LIVER; LUNG; MALE; MELANOMA; METASTASIS; POSITRON EMISSION TOMOGRAPHY; RADIATION DOSE; STEREOTACTIC BODY RADIATION THERAPY; UNIVARIATE ANALYSIS; WHOLE BODY RADIATION; KIDNEY TUMOR; METHODOLOGY; MIDDLE AGED; MORTALITY; PATHOLOGY; RADIATION RESPONSE; RADIOSURGERY; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; KIDNEY NEOPLASMS; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; RADIOSURGERY; RETROSPECTIVE STUDIES;

EID: 79953740080     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-6-34     Document Type: Article

References (36)

1. Vaeth JM. Proceedings: Cancer of the kidney--radiation therapy and its indications in non-Wilms' tumors. Cancer 1973, 32:1053-1055. 10.1002/1097-0142(197311)32:5<1053::AID-CNCR2820320504>3.0.CO;2-Y, 4202186.
2. Dewey DL. The radiosensitivity of melanoma cells in culture. Br J Radiol 1971, 44:816-817. 10.1259/0007-1285-44-526-816, 5165659.
3. Habermalz HJ, Fischer JJ. Radiation therapy of malignant melanoma: experience with high individual treatment doses. Cancer 1976, 38:2258-2262. 10.1002/1097-0142(197612)38:6<2258::AID-CNCR2820380611>3.0.CO;2-H, 1000466.
4. Onufrey V, Mohiuddin M. Radiation therapy in the treatment of metastatic renal cell carcinoma. Int J Radiat Oncol Biol Phys 1985, 11:2007-2009. 10.1016/0360-3016(85)90285-8, 2414257.
5. Halperin EC, Harisiadis L. The role of radiation therapy in the management of metastatic renal cell carcinoma. Cancer 1983, 51:614-617. 10.1002/1097-0142(19830215)51:4<614::AID-CNCR2820510411>3.0.CO;2-J, 6185207.
6. Overgaard J, von der Maase H, Overgaard M. A randomized study comparing two high-dose per fraction radiation schedules in recurrent or metastatic malignant melanoma. Int J Radiat Oncol Biol Phys 1985, 11:1837-1839. 10.1016/0360-3016(85)90042-2, 4044346.
7. Sause WT, Cooper JS, Rush S, Ago CT, Cosmatos D, Coughlin CT, JanJan N, Lipsett J. Fraction size in external beam radiation therapy in the treatment of melanoma. Int J Radiat Oncol Biol Phys 1991, 20:429-432. 10.1016/0360-3016(91)90053-7, 1995527.
8. Brown PD, Brown CA, Pollock BE, Gorman DA, Foote RL. Stereotactic radiosurgery for patients with "radioresistant" brain metastases. Neurosurgery 2002, 51:656-665. discussion 665-657, 10.1097/00006123-200209000-00009, 12188943.
9. Clarke JW, Register S, McGregor JM, Grecula JC, Mayr NA, Wang JZ, Li K, Gupta N, Kendra KL, Olencki TE, et al. Stereotactic radiosurgery with or without whole brain radiotherapy for patients with a single radioresistant brain metastasis. Am J Clin Oncol 33:70-74. 10.1097/COC.0b013e31819ccc8c, 19652578.
10. Hara W, Tran P, Li G, Su Z, Puataweepong P, Adler JR, Soltys SG, Chang SD, Gibbs IC. Cyberknife for brain metastases of malignant melanoma and renal cell carcinoma. Neurosurgery 2009, 64:A26-32. 10.1227/01.NEU.0000339118.55334.EA, 19165071.
11. Marko NF, Angelov L, Toms SA, Suh JH, Chao ST, Vogelbaum MA, Barnett GH, Weil RJ. Stereotactic radiosurgery as single-modality treatment of incidentally identified renal cell carcinoma brain metastases. Surg Neurol 2009,
12. Nguyen QN, Shiu AS, Rhines LD, Wang H, Allen PK, Wang XS, Chang EL. Management of spinal metastases from renal cell carcinoma using stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 76:1185-1192.
13. Chang EL, Selek U, Hassenbusch SJ, Maor MH, Allen PK, Mahajan A, Sawaya R, Woo SY. Outcome variation among "radioresistant" brain metastases treated with stereotactic radiosurgery. Neurosurgery 2005, 56:936-945. discussion 936-945.
14. Walsh L, Stanfield JL, Cho LC, Chang CH, Forster K, Kabbani W, Cadeddu JA, Hsieh JT, Choy H, Timmerman R, Lotan Y. Efficacy of ablative high-dose-per-fraction radiation for implanted human renal cell cancer in a nude mouse model. Eur Urol 2006, 50:795-800. discussion 800, 10.1016/j.eururo.2006.03.021, 16632182.
15. Jhaveri P, Teh BS, Bloch C, Amato R, Butler EB, Paulino AC. Stereotactic body radiotherapy in the management of painful bone metastases. Oncology (Williston Park) 2008, 22:782-788. discussion 788-789, 796-787.
16. Wersall PJ, Blomgren H, Lax I, Kalkner KM, Linder C, Lundell G, Nilsson B, Nilsson S, Naslund I, Pisa P, Svedman C. Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma. Radiother Oncol 2005, 77:88-95. 10.1016/j.radonc.2005.03.022, 15972239.
17. Rusthoven KE, Kavanagh BD, Burri SH, Chen C, Cardenes H, Chidel MA, Pugh TJ, Kane M, Gaspar LE, Schefter TE. Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J Clin Oncol 2009, 27:1579-1584. 10.1200/JCO.2008.19.6386, 19255320.
18. Rusthoven KE, Kavanagh BD, Cardenes H, Stieber VW, Burri SH, Feigenberg SJ, Chidel MA, Pugh TJ, Franklin W, Kane M, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol 2009, 27:1572-1578. 10.1200/JCO.2008.19.6329, 19255321.
19. Park C, Papiez L, Zhang S, Story M, Timmerman RD. Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy. Int J Radiat Oncol Biol Phys 2008, 70:847-852. 10.1016/j.ijrobp.2007.10.059, 18262098.
20. Schefter TE, Kavanagh BD, Timmerman RD, Cardenes HR, Baron A, Gaspar LE. A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases. Int J Radiat Oncol Biol Phys 2005, 62:1371-1378. 10.1016/j.ijrobp.2005.01.002, 16029795.
21. Goitein M, Schultheiss TE. Strategies for treating possible tumor extension: some theoretical considerations. Int J Radiat Oncol Biol Phys 1985, 11:1519-1528. 10.1016/0360-3016(85)90341-4, 4019276.
22. Fowler JF, Tome WA, Fenwick JD, Mehta MP. A challenge to traditional radiation oncology. Int J Radiat Oncol Biol Phys 2004, 60:1241-1256. 10.1016/j.ijrobp.2004.07.140, 15519797.
23. Lea DE CD. The mechanism of the induction by radiation of chromosome aberrations in Tradescantia. Journal of Genetics 1942, 44:216-245.
24. Garcia-Barros M, Paris F, Cordon-Cardo C, Lyden D, Rafii S, Haimovitz-Friedman A, Fuks Z, Kolesnick R. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 2003, 300:1155-1159. 10.1126/science.1082504, 12750523.
25. Deschavanne PJ, Fertil B. A review of human cell radiosensitivity in vitro. Int J Radiat Oncol Biol Phys 1996, 34:251-266. 10.1016/0360-3016(95)02029-2, 12118559.
26. Powell JW, Chung CT, Shah HR, Canute GW, Hodge CJ, Bassano DA, Liu L, Mitchell L, Hahn SS. Gamma Knife surgery in the management of radioresistant brain metastases in high-risk patients with melanoma, renal cell carcinoma, and sarcoma. J Neurosurg 2008, 109(Suppl):122-128.
27. Katz AW, Carey-Sampson M, Muhs AG, Milano MT, Schell MC, Okunieff P. Hypofractionated stereotactic body radiation therapy (SBRT) for limited hepatic metastases. Int J Radiat Oncol Biol Phys 2007, 67:793-798. 10.1016/j.ijrobp.2006.10.025, 17197128.
28. Herfarth KK, Debus J, Lohr F, Bahner ML, Rhein B, Fritz P, Hoss A, Schlegel W, Wannenmacher MF. Stereotactic single-dose radiation therapy of liver tumors: results of a phase I/II trial. J Clin Oncol 2001, 19:164-170.
29. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol 1995, 13:8-10.
30. Thelen A, Jonas S, Benckert C, Lopez-Hanninen E, Rudolph B, Neumann U, Neuhaus P. Liver resection for metastases from renal cell carcinoma. World J Surg 2007, 31:802-807. 10.1007/s00268-007-0685-9, 17354021.
31. Yang JC, Abad J, Sherry R. Treatment of oligometastases after successful immunotherapy. Semin Radiat Oncol 2006, 16:131-135. 10.1016/j.semradonc.2005.12.008, 16564448.
32. Assouad J, Petkova B, Berna P, Dujon A, Foucault C, Riquet M. Renal cell carcinoma lung metastases surgery: pathologic findings and prognostic factors. Ann Thorac Surg 2007, 84:1114-1120. 10.1016/j.athoracsur.2007.04.118, 17888956.
33. Sherry RM, Pass HI, Rosenberg SA, Yang JC. Surgical resection of metastatic renal cell carcinoma and melanoma after response to interleukin-2-based immunotherapy. Cancer 1992, 69:1850-1855. 10.1002/1097-0142(19920401)69:7<1850::AID-CNCR2820690729>3.0.CO;2-I, 1551067.
34. Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 2004, 171:1071-1076. 10.1097/01.ju.0000110610.61545.ae, 14767273.
35. Henderson MA, Hoopes DJ, Fletcher JW, Lin PF, Tann M, Yiannoutsos CT, Williams MD, Fakiris AJ, McGarry RC, Timmerman RD. A pilot trial of serial 18F-fluorodeoxyglucose positron emission tomography in patients with medically inoperable stage I non-small-cell lung cancer treated with hypofractionated stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 2010, 76:789-795. 10.1016/j.ijrobp.2009.02.051, 2823932, 19473777.
36. Hoopes DJ, Tann M, Fletcher JW, Forquer JA, Lin PF, Lo SS, Timmerman RD, McGarry RC. FDG-PET and stereotactic body radiotherapy (SBRT) for stage I non-small-cell lung cancer. Lung Cancer 2007, 56:229-234. 10.1016/j.lungcan.2006.12.009, 17353064.